PATENT CLAIM ANALYSIS

Application Number: 16202210
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-03
Patent Classification: ["514", "230500"]

Abstract:
The present invention provides methods and uses of inhibitors of histone deacetylase 11 (HDAC11) in the treatment of diseases and/or disorders, such as, for example, cell proliferative diseases.

Claim (Index 10):
The method of any one of  claims 7 - 9 , wherein the cancer is esophageal squamous cell carcinoma, oral squamous cell carcinoma, lung, squamous cell carcinoma, lung adenocarcinoma, non-small cell lung cancer, small cell lung cancer or sinonasal cancer.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 98.0
- Lexical Diversity: 1.17241
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['16202207', '15234412', '13683880', '11687565', '14763013']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7770703318412658
- 35 USC 102 Novelty (BERT): 0.5787928560552748
- Combined Prediction Score: 0.7572425842626668
- Mean Citation Score: 375.980184
- Max Citation Score: 624.77814
- Similarity Product: 334.21263914187665

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test